Lantheus (NASDAQ:LNTH) Hits New 12-Month High – Time to Buy?

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) reached a new 52-week high on Thursday . The stock traded as high as $104.50 and last traded at $104.32, with a volume of 1223938 shares traded. The stock had previously closed at $100.24.

Analyst Ratings Changes

LNTH has been the topic of several research analyst reports. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Mizuho upped their price target on Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, May 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 price target on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Truist Financial reaffirmed a “buy” rating and set a $115.00 price target (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Price Performance

The firm has a market capitalization of $6.79 billion, a P/E ratio of 25.14 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The business has a 50 day simple moving average of $89.53 and a two-hundred day simple moving average of $76.10.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 4.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantheus

A number of institutional investors have recently added to or reduced their stakes in the business. M&T Bank Corp bought a new position in shares of Lantheus during the 4th quarter valued at about $370,950,000. Farallon Capital Management LLC increased its position in shares of Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares during the last quarter. Norges Bank bought a new position in shares of Lantheus during the 4th quarter valued at about $76,197,000. Freestone Grove Partners LP increased its position in shares of Lantheus by 4,114.8% during the 4th quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after purchasing an additional 594,088 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Lantheus by 686.1% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock valued at $45,423,000 after purchasing an additional 522,678 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.